DMAA — Drugs Made In America Acquisition Cashflow Statement
0.000.00%
Last trade - 00:00- $263.89m
- $264.22m
Annual cashflow statement for Drugs Made In America Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | 10-K | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | 0 | -0.28 | 5.94 |
| Non-Cash Items | — | 0.03 | -6.62 |
| Other Non-Cash Items | |||
| Changes in Working Capital | — | 0.077 | 0.139 |
| Change in Prepaid Expenses | |||
| Change in Accrued Expenses | |||
| Change in Payable / Accrued Expenses | |||
| Cash from Operating Activities | 0 | -0.172 | -0.539 |
| Other Investing Cash Flow Items | — | — | -231 |
| Change in Net Investments | |||
| Cash from Investing Activities | — | — | -231 |
| Financing Cash Flow Items | — | -0.364 | 233 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | — | 0.174 | 232 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 0 | 0.001 | 0.005 |